🎯 Drug Targets

Browse 6 drug targets with druggability analysis, composite scores, and clinical context

Targets

High Druggability

0.60

Avg Score

Target Classes

Druggability Distribution

High: 0Medium: 0Low: 6Unknown: 0

Avg druggability score: 0.404

Clinical Pipeline

Approved: 2Phase III: 2Phase II: 2Phase I: 0Preclinical: 0

Total compounds: 14 · Approved: 0

Filtered by: class=receptor, druggability=Low — 6 results

TFR1 Transferrin receptor protein 1 Phase 4

Receptor Low Druggability

Monoclonal antibodies targeting receptor or iron chelation affecting iron uptake

TLR4 Toll-like receptor 4 Phase 3

Receptor Low Druggability

Small molecule antagonist or antibody blocking TLR4-mediated neuroinflammatory signaling

TREM2 Triggering receptor expressed on myeloid cells 2 Phase 2

Receptor Low Druggability

Agonist antibodies that enhance TREM2 signaling to promote microglial function

SDC1 Syndecan-1 Phase 2

Receptor Low Druggability

Small molecule modulation of heparan sulfate interactions or shedding

LRP1 LDL receptor related protein 1 Phase 3

Receptor Low Druggability

Modulation of receptor-mediated endocytosis and clearance pathways

IGF2R Insulin-like growth factor 2 receptor Phase 4

Receptor Low Druggability

Drugs targeting IGF2R typically work by blocking IGF2 binding and signaling through the IGF1R/IGF2R axis, thereby inhibiting mitogenic and anti-apoptotic effects in cancer cells. Alternatively, agents may enhance IGF2 clearance through IGF2R-mediated endocytosis to reduce circulating IGF2 levels and downstream signaling.